Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

NCT00020254 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: recombinant fowlpox-prostate specific antigen vaccine
BIOLOGICAL: recombinant vaccinia prostate-specific antigen vaccine
BIOLOGICAL: recombinant vaccinia-B7.1 vaccine
BIOLOGICAL: sargramostim
DRUG: nilutamide

Sponsor

National Cancer Institute (NCI)